Intersect ENT is an ear, nose and throat medical technology company. Co.'s steroid releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL® family of products (PROPEL®, PROPEL® Mini and PROPEL® Contour) and the SINUVA® (mometasone furoate) Sinus Implant. The PROPEL family of products are used to reduce inflammation and maintain patency following sinus surgery.SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. We show 33 historical shares outstanding datapoints in our coverage of XENT's shares outstanding history.
Understanding the changing numbers of XENT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XENT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XENT by allowing them to research XENT shares outstanding history
as well as any other stock in our coverage universe. |
Free XENT Email Alerts:
Video: Shares Outstanding Importance
